>
Synairgen logo

SNG - Synairgen Share Price

98.9p -1.2  -1.2%

Last Trade - 14/05/21

Sector
Healthcare
Size
Small Cap
Market Cap £197.7m
Enterprise Value £122.9m
Revenue £n/a
Position in Universe 846th / 1826
Bullish
Bearish
Unlock SNG Revenue
Momentum
Relative Strength (%)
1m -34.7%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -61.7%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.025 0.000 5.03 0.11 0.000 0.000 146.5 583 -100.0%
+356.2
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020,Synairgen plc revenues was not reported. Net loss increasedfrom £3.9M to £13.9M. Higher net loss reflects Research anddevelopment expenditure increase from £3.5M to £15.5M(expense), Other Administrative Expenses increase of 66% to£2.2M (expense), Finance income decrease of 37% to £19K(income). Basic Earnings per Share excluding ExtraordinaryItems decreased from -£0.04 to -£0.09.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for SNG
Graphical History

Revenue

SNG Revenue Unlock SNG Revenue

Net Income

SNG Net Income Unlock SNG Revenue

Normalised EPS

SNG Normalised EPS Unlock SNG Revenue

PE Ratio Range

SNG PE Ratio Range Unlock SNG Revenue

Dividend Yield Range

SNG Dividend Yield Range Unlock SNG Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
SNG EPS Forecasts Unlock SNG Revenue
Profile Summary

Synairgen plc is a holding company. The Company is engaged in the drug discovery and development of therapies for respiratory diseases, particularly in the areas, including severe asthma, chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF). The Company uses its human biology BioBank platform to discover and develop therapies for respiratory disease. Using the BioBank platform, it has developed a number of tissue models, which include In vitro and Ex vivo models. The Company's primary asset is AZD9412, which is an inhaled interferon beta (IFN-beta) therapy. AZD9412 is outlicensed to AstraZeneca for the clinical development and commercialization, and is in a confirmatory Phase II trial. Its drug programs include IFN-b (SNG001) for Asthma and COPD, and Lysyl oxidase-like protein 2 (LOXL2) inhibitors for IPF. The Company's subsidiary includes Synairgen Research Limited, which is engaged in the drug discovery and development.

Directors
Last Annual December 31st, 2020
Last Interim December 31st, 2020
Incorporated September 16, 2004
Public Since October 26, 2004
No. of Shareholders: n/a
No. of Employees: 14
Sector Healthcare
Industry Biotechnology & Medical Research
Index FTSE Aim All Share ,
Exchange London Stock Exchange (AIM)
Shares in Issue 199,914,402
Free Float (0.0%)
Eligible for
ISAs
SIPPs
SNG Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for SNG
Upcoming Events for SNG
Monday 24th May, 2021 Estimate
Full Year 2020 Synairgen PLC Earnings Release
Tuesday 29th June, 2021 Estimate
Synairgen PLC Annual Shareholders Meeting
Frequently Asked Questions for Synairgen
What is the Synairgen share price?

As of 14/05/21, shares in Synairgen are trading at 98.9p, giving the company a market capitalisation of £197.7m. This share price information is delayed by 15 minutes.

How has the Synairgen share price performed this year?

Shares in Synairgen are currently trading at 98.9p and the price has moved by 84.24% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Synairgen price has moved by 48.12% over the past year.

What are the analyst and broker recommendations for Synairgen?

Of the analysts with advisory recommendations for Synairgen, there are there are currently 1 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Synairgen is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Synairgen next release its financial results?

Synairgen is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Synairgen dividend yield?

Synairgen does not currently pay a dividend.

Does Synairgen pay a dividend?

Synairgen does not currently pay a dividend.

When does Synairgen next pay dividends?

Synairgen does not currently pay a dividend.

How do I buy Synairgen shares?

To buy shares in Synairgen you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Synairgen?

Shares in Synairgen are currently trading at 98.9p, giving the company a market capitalisation of £197.7m.

Where are Synairgen shares listed? Where are Synairgen shares listed?

Here are the trading details for Synairgen:

Country of listing: United Kingdom
Exchange: LSE
Ticker Symbol: SNG
What kind of share is Synairgen?

Based on an overall assessment of its quality, value and momentum, Synairgen is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Synairgen share price forecast 2021?

Shares in Synairgen are currently priced at 98.9p. At that level they are trading at 0.653% discount to the analyst consensus target price of 99.55.

Analysts covering Synairgen currently have a consensus Earnings Per Share (EPS) forecast of 0.4815 for the next financial year.

How can I tell whether the Synairgen share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Synairgen. Over the past six months, the relative strength of its shares against the market has been -24.79%. At the current price of 98.9p, shares in Synairgen are trading at -38.25% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Synairgen PE Ratio?

We were not able to find PE ratio data for Synairgen.

Who are the key directors of Synairgen?

Synairgen's management team is headed by:

Simon James Blouet Shaw - NEC
Richard Marsden - MDR
John Ward - FID
Stephen Holgate - NED
Bruce Campbell - NED
Phillip Monk - CSO
Iain Peter Murray Buchanan - NED
Who are the major shareholders of Synairgen?

Here are the top five shareholders of Synairgen based on the size of their shareholding:

Polar Capital Biotechnology Fund Mutual Fund
Percentage owned: 9.79% (19.6m shares)
Polar Capital LLP Investment Advisor/Hedge Fund
Percentage owned: 8.87% (17.7m shares)
Polygon Global Partners LLP Hedge Fund
Percentage owned: 5% (10.00m shares)
Acacia Research Corp Investment Advisor
Percentage owned: 1.6% (3.19m shares)
Jupiter UK Smaller Companies Equity Fund Mutual Fund
Percentage owned: 1.39% (2.77m shares)
Similar to SNG
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.